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Abstract
Background: Resistant hypertension is defined as an uncontrolled blood pressure despite treatment at best-tolerated
doses with at least three antihypertensive agents including a diuretic. It is an emerging public health problem. At
present clinical trial data on management of resistant hypertension is limited. Management is largely based
on observational studies and expert opinions. Propranolol is a nonselective beta blocker. Several studies have
confirmed that propranolol has a significant hypotensive action, both when used alone and as an adjuvant
therapy. At present there are no prospective, randomized, clinical studies evaluating the effectiveness of propranolol in
patients with resistant hypertension. Therefore, we have designed a prospective randomized trial to evaluate the safety
and efficacy of propranolol in patients with resistant hypertension.
Methods/design: The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for
a period of 3 months. The study has been approved by the Ethics Review Committee of the Faculty of Medicine,
University of Colombo. A total of 200 adults with resistant hypertension will be recruited for the study. They will be
randomly assigned to the test and placebo groups on a 1:1 ratio. The test group will receive propranolol 40 mg three
times a day and the control group will receive an identical placebo capsule. The study drugs will be double blinded to
both investigators and subjects. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit
1), 2 months (visit 2) and 3 months (visit 3). The primary outcomes of the study is to find a statistically significant
difference between the fall in mean systolic and mean diastolic blood pressure measured by ABPM (ambulatory blood
pressure monitoring) from baseline between the two groups. Data will be analyzed using SPSS v16.
Discussion: To our knowledge this is one of the first randomized controlled trials evaluating the effects of propranolol
in resistant hypertension. This study will provide the necessary groundwork for future large-scale, multicentered clinical
trials. The result, positive or negative, should provide a step change in the evidence guiding current and future policies
regarding treatment of resistant hypertension.
Trial registration: Sri Lanka Clinical Trials Registry, identifier: SLCTR/2016/002. Registered on 27 January 2016; Study
protocol version 2.1.
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Background
Resistant hypertension is defined as an uncontrolled
blood pressure despite treatment (>140/90 mmHg or
>150/90 mmHg in patients over the age of 60 years)
with at least three antihypertensive agents at best-
tolerated doses, including a diuretic [1, 2]. It is an emer-
ging public health problem, associated with substantial
morbidity and mortality [3, 4]. Studies indicate that the
prevalence of resistant hypertension is 10–20% in the
general hypertensive population [5, 6].
At present clinical trial data on management of resistant
hypertension is limited. Management is largely based on
observational studies and expert opinions. Recent studies
support the use of spironolactone as the “first-line” fourth
drug for treating resistant hypertension [7, 8]. However, to
date there have been no randomized clinical trials com-
paring the effectiveness of various drug combinations in
the treatment of resistant hypertension [9]. Though
sympathetic denervation showed some promise in the
treatment of resistant hypertension from the initial stud-
ies, subsequent studies failed to show a sustained long-
term reduction of blood pressure [10].
Propranolol is a nonselective beta blocker. Several stud-
ies have confirmed that propranolol has a significant
hypotensive action, both when used alone and as an adju-
vant therapy [11]. However, the exact mechanism of the
antihypertensive effect of propranolol is still poorly under-
stood. It is possible that the hypotensive effect of propran-
olol is not only due to its peripheral beta-receptor
blocking action [12]. Propranolol, with its high lipophilic
tendency, achieves high concentrations in cerebrospinal
fluid and blocks the central cardiac sympathetic outflow.
Increased sympathetic nervous system activity has been
documented in systole-diastolic hypertension and in iso-
lated systolic hypertension [13]. Furthermore, sympathetic
nervous system activity increases progressively and in par-
allel with stages of hypertension [14]. Central sympathetic
outflow blockage may be important in reducing transient
rises in blood pressure which occurs in response to vari-
ous stimuli. In addition, propranolol is also known to act
through the renin-angiotensin system to produce
hypotension [15]. The role of stress as a risk factor for re-
sistant hypertension also needs to be considered as drugs
alone have not been very successful in controlling blood
pressure in patients with resistant hypertension [16]. Pro-
pranolol is sometimes used as an anxiolytic in the pre-
medication of surgical patients [17]. Hence, propranolol
may be beneficial in reducing stress and anxiety in
patients with resistant hypertension. At present there are
no prospective, randomized, clinical studies evaluating the
effectiveness of propranolol in patients with resistant
hypertension. Therefore, we designed a prospective
randomized trial to evaluate the efficacy and safety of pro-
pranolol in patients with this condition.
Methods/design
Objectives and hypothesis
Hypothesis: blood pressure in patients with resistant
hypertension treated with propranolol will be lower than
that of the control group.
Primary objective: the study aims to compare the safety
and efficacy of propranolol in patients with resistant hyper-
tension when added to a multidrug combination (at least
three drugs) consisting of a diuretic and an angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin-II recep-
tor blocker (ARB), a centrally acting drug, and an alpha
blocker or calcium channel blocker.
Secondary objectives: (1) to describe the sociodemo-
graphic and clinical characteristics of patients with resistant
hypertension at baseline, (2) to describe the complications
and cardiovascular risk associations of patients with resist-
ant hypertension at baseline, (c) to describe the impact of
propranolol administration on serum/urinary electrolytes
and oxidative stress in patients with resistant hypertension
and (4) to assess sodium excretion in patients with resistant
hypertension at baseline and following propranolol therapy.
Study design
The study will be conducted as a randomized, double-
blind, placebo-controlled clinical trial for a period of
3 months to assess the efficacy of using propranolol in the
management of patients with resistant hypertension at the
medical outpatient clinics of the National Hospital of Sri
Lanka, Colombo, Sri Lanka. Figure 1 provides an overview
of the study. This protocol was written following the
Standard Protocol Items: Recommendations for Interven-
tional trials (SPIRIT) Checklist (see Additional file 1). The
schedule of trial enrollment, interventions and assess-
ments is presented in Fig. 2.
Sample size
The sample size calculation was based on formulae for
analysis between differences of means. The value for alpha
was set at 0.05 and the value for 1 − beta was set at 0.9.
Sample sizes were calculated for a difference of systolic
blood pressure by 10 mmHg and diastolic blood pressure
by 5 mmHg. Standard deviation values were taken as
18 mmHg for systolic blood pressure and 10.7 mmHg for
diastolic blood pressure as per prior investigations on pa-
tients with resistant hypertension. Using the above parame-
ters the calculated sample sizes were 140 and 180 patients
to detect differences in systolic and diastolic blood pres-
sures, respectively. Using the greater number and adjusting
for dropout and noncompliance rates a sample of 200 pa-
tients will be recruited with a 1:1 allocation per group.
Population
Resistant hypertension is defined as casual blood pres-
sure during clinical examination of more than 140/
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90 mmHg (in patients below 60 years of age or with
diabetes mellitus) or more than 150/90 mmHg (in patients
above 60 years of age) despite treatment with a multidrug
combination consisting of a diuretic and an ACEI/ARB, a
centrally acting drug, and an alpha blocker or calcium
channel blocker [18]. All reference blood pressures will be
taken as a mean of the 2nd and 3rd measurements during
a single examination measured at least 3 min apart.
Inclusion and exclusion criteria
Inclusion criteria
Both genders aged between 18 and 75 years and eligible
for the study through screening confirming the presence
of resistant hypertension as defined above.
Exclusion criteria
 Patients with a systolic blood pressure value over
220 mmHg requiring immediate adjustments of
therapy
 Patients with moderate to severe renal insufficiency
(acute or chronic) with glomerular filtration rate of
less than 30 ml/min
 Patients with active bronchospastic disorders
 Heart failure classes III and IV
 Severe bradycardia (heart rate below 50/min), 2nd
and 3rd degree AV block
 Pregnant or lactating women
 Patients with a history of hypersensitivity to any of
the drugs under study
 Patients already using beta blockers
Suspension criteria
 Subject’s demand to discontinue the study
 Serious adverse events or unusual changes in
clinical test results
 Principal investigator’s decision to terminate the
study (low rates of compliance, complications, or
unable to sustain the study for various reasons)
Randomization
Randomization will be performed using computer-
generated random number allocation tables generated by
SPSS v16.0 software package (SPSS Inc., Chicago, IL,
USA), based on a 1:1 allocation between groups. Patients
will be assigned a recruitment number once they provide
informed written consent. Each recruitment number will
be subsequently allocated a computer-generated study
number with a corresponding treatment kit number.
These kit numbers will determine allocation to the treat-
ment group or placebo group. The personnel administer-
ing the study medication will be blinded to the treatment
group. Random number allocation tables and lists will be
maintained in password-protected files accessible only in
the event where unblinding is deemed necessary.
Blinding
The study drugs are double blinded to both investigators
and subjects. The drug manufacturing will be done by
Astron Lanka (PVT) Ltd., Colombo, Sri Lanka, and they
will be responsible for the labeling of the capsules with
code numbers.
Interventions
The treatment drug is a capsule containing propran-
olol 40 mg as the active ingredient. The placebo will
be manufactured to have a similar appearance, shape,
weight, taste and color as the propranolol 40-mg
capsule. The subjects will receive either propranolol
40 mg or an identical placebo taken three times a
day for a period of 3 months.
Fig. 1 Study flow chart
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Study groups
(a)Treatment group: propranolol capsule and standard
treatments
(b)Control group: placebo capsule and standard
treatments
Study period
The study will be conducted for a period of 3 months.
The visits and the evaluations will be done as follows:
screening (visit 0), 1 month (visit 1), 2 months (visit 2)
and 3 months (visit 3).
Outcomes
Primary outcomes: the primary outcomes of the study
are to find a statistically significant difference between
the fall in mean systolic and mean diastolic blood
pressure measured by ABPM (ambulatory blood
pressure monitoring) from baseline between the two
groups.
Secondary outcomes:
 To determine the difference in cardiovascular
outcomes, including acute coronary syndrome,
acute stroke and acute heart failure, between groups
Fig. 2 Schedule of enrollment, interventions and assessments (Standard Protocol Items: Recommendations for Interventional trials (SPIRIT) figure)
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 To determine the variations in plasma and urinary
electrolytes between the two groups at measured
endpoints
 To assess renal outcomes as measured by the
glomerular filtration rate between groups
 To determine variations in plasma renin activity
(PRA) and angiotensin:aldosterone ratios between
the study groups
 To determine differences in oxidative stress between
the study groups using nitric oxide as a surrogate
marker
 To assess safety outcomes, including the incidence




Participants will be recruited from the outpatient medical
clinics of the National Hospital of Sri Lanka, Colombo, Sri
Lanka.
Study schedule
The detailed items that will be measured at every visit
are described in Fig. 2. During the screening visit, the
following baseline examinations will be carried out.
Pulse rate and blood pressure measurements in the
office (a mean of the 2nd and 3rd measurements on a
seated patient during a single examination, three blood
pressure measurements will be taken at least 3 min apart
from each other). During this screening visit patients
will be evaluated for compliance and other factors for
lack of control such as failure to adhere to lifestyle ad-
vices, poor blood pressure measurement technique and
the use of medications that interfere with blood pres-
sure. This will be followed by a run-in period of 4 to
8 weeks where patients identified as having resistant
hypertension will be subjected to optimization of their
existing drug regimen. The drug dosages will be adjusted
to the maximum recommended dose or the maximum
tolerated dose. After the run-in period patients will be en-
rolled into the study if they fulfill the inclusion and exclu-
sion criteria. This will be the enrollment visit. In this visit
serum urea, creatinine, sodium, potassium and PRA and
aldosterone levels will be measured. Estimation of sodium
and potassium excretion will also take place with a 24-h
estimation of urinary electrolytes. Baseline oxidative stress
will be assessed by estimation of nitric oxide levels. An
electrocardiogram will be taken to assess cardiac rhythm.
During this visit 24-h ABPM, using a monitor validated to
the standards of the British Hypertension Society (BHS),
will be undertaken. The mean daytime blood pressure will
be calculated from values measured between 9:00 a.m.
and 11:00 p.m., the mean night blood pressure from values
measured between 1:00 a.m. and 6:00 a.m. The mean 24-h
blood pressure will be calculated as the mean of all the
measured values [19]. This will enable us to exclude pa-
tients with white coat hypertension.
After randomization patients will enter the clinical trial
and will be given either propranolol 40 mg three times a
day or a placebo which will be added to the patients’ rou-
tine medication. At the first two follow-up visits (visits 1
and 2) the following examinations and investigations will
be performed: pulse rate and blood pressure measure-
ments (as detailed above), measurements of serum so-
dium, potassium, urea and creatinine levels and an
electrocardiogram. During the follow-up visits, if blood
pressure is not controlled both drug and placebo dose will
be doubled once (maximum dose of propranolol used in
this study will be 80 mg three times daily). Three months
after initiation of the drug, final examination of the pa-
tients will be carried out (visit 3), as described in Fig. 2.
Measurement tools
Anthropometric measurements
Body weight will be measured using a calibrated elec-
tronic floor scale (SECA 815 by SECA GmbH & Co. Kg.,
Hamburg, Germany) to the nearest 0.1 kg. Height will
be measured to the nearest 0.1 cm using an upright plas-
tic portable Stadiometer (SECA 217 by SECA GmbH &
Co. Kg., Hamburg, Germany). Body Mass Index (BMI)
will be calculated as weight (in kilograms) divided by the
square of height (in meters). Waist circumference (WC)
will be measured with a nonelastic tape (SECA 203 by
SECA GmbH & Co. Kg., Hamburg, Germany) at a point
midway between the lower border of the rib cage and
the iliac crest at the end of normal expiration. Similarly,
hip circumference also will be measured at the widest
part of the buttocks at the intertrochanteric level to the
nearest 0.1 cm. All anthropometric measurements will
be made by using standard equipment and following
World Health Organization (WHO) guidelines.
Compliance calculation
Subjects will be asked to return any remaining drugs
and their compliance will be evaluated by using the for-
mula given below:





Parametric and nonparametric statistical tests will be
applied using the SPSS version 16 (SPSS Inc., Chicago,
IL, USA) and Stata/SE 10.0 (StataCorp Inc., College
Station, TX, USA) for data analysis. Descriptive data will
be analyzed for linearity and will be expressed as
percentages, median and mean. The two groups will be
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compared for uniformity on sociodemographic variables,
clinical manifestations and laboratory parameters at
baseline. After completion, primary and secondary out-
comes will be compared in the groups using statistical
methods for comparison of means and using regression
analysis. For each of the outcomes, multilevel regression
analysis will be used to examine differences between trial
arms. For binary outcomes the model will be logistic and
for continuous outcomes the model will be linear regres-
sion. All analyses will follow intention-to-treat principles
and a prespecified analysis plan. Where appropriate, sen-
sitivity analyses will be conducted (for example, control
for additional covariates; and bootstrapped p values for
skewed outcomes). In the case of missing data values,
we will apply mean imputation and regression imput-
ation where rates are low, and consider multiple imputa-
tions where they exceed 10%. A p value < 0.05 will be
considered significant.
Adverse effect evaluation
Described adverse effects of propranolol include: aggrava-
tion of congestive heart failure, bradycardia, hypotension,
arthropathy, Raynaud’s phenomenon, hyper/hypoglycemia,
depression, fatigue, insomnia, paresthesia, psychotic dis-
order, pruritus, nausea, vomiting, hyperlipidemia, hyperka-
lemia, muscle cramps, bronchospasm, dyspnea, pulmonary
edema and respiratory distress. In the event of a probable
adverse reaction, the following precautions would ensure
timely identification and management of patients:
 Reporting: mechanisms would be put in place to
ensure direct reporting of probable adverse events to
the investigator by patients (via telephone, which
will be available 24 h on all days)
 During follow-up visits, probable adverse events will
be noted by history and examination and investi-
gated upon in detail. The attending physician will
assess for any symptoms and signs of the potential
side effects. All adverse effects observed will be
documented in the Case Record Form (CRF)
 All serious adverse events will be reported to the
Ethics Review Committee (ERC), Faculty of
Medicine, University of Colombo, and the National
Pharmaco-vigilance Unit of the Department of
Pharmacology, Faculty of Medicine, University of
Colombo
 An independent Data Safety Monitoring Board
(DSMB), consisting of clinical pharmacologists,
physicians and members of the ERC, will evaluate all
adverse events at regular intervals
 Termination of study: in the event of major adverse
effects occurring in a significant proportion of the
study population the study would be terminated
pending further investigation
Data collection
Data collection will be performed according to standard
operating procedures by medically trained research
assistants (RAs).
Data and biological sample handling
Data will be entered by a minimum number of dedicated
staff and saved in a dedicated password-protected
computer. The data collection forms will be preserved
securely. Only the investigators will have access to the
computer database and the data collection forms. Blood
samples will be stored in a secure facility, with secure
measures taken to ensure that specimens are kept in
appropriate conditions at all times when in storage. Stor-
age technologies, with the capability of monitoring the
temperature of samples around the clock, would be
utilized. After each analysis has been completed and
with the approval of the principal investigator, the sam-
ples stored in the storage facility may be disposed of by
the sample custodian. A Sample Disposal Sheet (SDS)
will be completed and kept for future reference.
Dissemination of study finding
The results of the above study will be published in local
and international peer-reviewed journals and presented
at international conferences and clinical meetings.
Ethical considerations
The study has been approved by the Ethics Review Com-
mittee (ERC) of the Faculty of Medicine, University of
Colombo (EC/15/152). The trial is also registered at the
Sri Lanka Clinical Trials Registry (SLCTR/2016/002).
The study will be conducted in compliance with the
Declaration of Helsinki and the Good Clinical Practice
(GCP) guidelines. No personal details will be collected
and confidentiality will be observed during the data
collection process. An investigator will meet the patients
in accordance with the inclusion criteria and describe
the study to them. Information will be given on the pur-
pose of the study, voluntary participation, interventions,
risks hazards and benefits, confidentiality and termin-
ation of participation. The information given above will
be further reinforced using an Information Sheet which
has been prepared in all three languages. Following this
informed written consent will be obtained using a
Consent Form after clarification of any questions the
participant may have regarding the study. If the partici-
pants require further clarification regarding the study
the contact numbers of the investigators will be provided
in the Information Sheet and the Consent Form. In the
event of the change in study protocol during the course
of the study, reconsent would be obtained from study
participants after explaining the necessity for such
change and the probable impact, if any, on the
Constantine et al. Trials  (2017) 18:124 Page 6 of 7
participant. The change in study protocol will be
informed to all relevant parties, including the ERC.
Discussion
In this paper, we present a clinical trial design to evalu-
ate the effects of propranolol in those with resistant
hypertension. To our knowledge this is one of the first
randomized controlled trials evaluating the effects of
propranolol in resistant hypertension. This study will
provide the necessary groundwork for future large-scale,
multicentered clinical trials. Given the current enthusi-
asm for using various drugs to improve blood pressure
control and metabolic parameters in those with resistant
hypertension, properly designed scientific evaluations
are a timely requirement. However, presently there are
no well-designed randomized control trials to support/
refute these arguments. The result, positive or negative,
should provide a step change in the evidence guiding
current and future policies regarding treatment of resist-
ant hypertension.
Trial status
Enrollment for the trial has not yet started.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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